| 2024-03-29 | TSPARMCD | Paired | ACTSUB | Actual Number of Subjects | C98703 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | ADAPT | Adaptive Design | C146995 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | ADDON | Added on to Existing Treatments | C49703 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | AGEMAX | Planned Maximum Age of Subjects | C49694 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | AGEMIN | Planned Minimum Age of Subjects | C49693 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | APPLCNT | Applicant | C204581 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | BIOSPRET | Biospecimen Retention Contains DNA | C126058 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CITNSTDY | Citation Used in Study | C127788 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CMSPSTAT | Commercial Sponsor Status | C127789 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | COMPTRT | Comparative Treatment Name | C68612 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CONEMAIL | Contact E-Mail Address | C176375 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CONMAIL | Contact Mailing Address | C176376 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CONNAME | Contact Name | C176373 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CONPHONE | Contact Phone Number | C176374 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CONROLE | Contact Role | C176372 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CRMDUR | Confirmed Response Minimum Duration | C98715 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CSRARDTC | Clinical Study Report Archive Date | C139273 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CTAUG | CDISC Therapeutic Area User Guide | C156602 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | CURTRT | Current Therapy or Treatment | C85582 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DCUTDESC | Data Cutoff Description | C98718 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DCUTDTC | Data Cutoff Date | C98717 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DGFCRIT | Delayed Graft Function Dx Criteria | C135514 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DMCIND | Data Monitoring Committee Indicator | C127790 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DOSE | Dose per Administration | C25488 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DOSFRM | Dose Form | C42636 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DOSFRQ | Dosing Frequency | C89081 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DOSRGM | Dose Regimen | C71137 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DOSU | Dose Units | C73558 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | DXCRIT | Diagnostic Criteria | C117960 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGBLIND | ECG Reading Blinded | C119560 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGCTMON | ECG Continuous Monitoring | C119561 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGLEADPR | ECG Planned Primary Lead | C119562 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGLEADSM | ECG Used Same Lead | C119563 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGRDMETH | ECG Read Method | C119564 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGREPLBL | ECG Replicates at Baseline | C119565 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGREPLTR | ECG Replicates On-Treatment | C119566 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EGTWVALG | ECG Twave Algorithm | C119582 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EMAILXML | Email Address for XML File | C127791 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EMPIPDCN | EMA Decision Number for PIP | C126059 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EPDISIND | Epi/Pandemic Related Disruption Ind | C171505 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EPIDEMIC | Name of Epi/Pandemic | C171506 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EURSBIND | EudraCT Resubmission Indicator | C126060 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EVSNDID | EudraVigilance Sender ID | C126061 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EVSNDORG | EudraVigilance Sender Organization | C126090 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EXPARECN | Expanded Access Record NCT Number | C127792 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EXPASTAT | Expanded Access Status | C127793 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | EXTTIND | Extension Trial Indicator | C139274 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | FCNTRY | Planned Country of Investigational Sites | C98770 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | FDADEIND | FDA-Regulated Device Study Indicator | C123629 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | FDADRIND | FDA-Regulated Drug Study Indicator | C123630 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | FDATCHSP | FDA Technical Specification | C156603 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | HLTSUBJI | Healthy Subject Indicator | C98737 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | INDIC | Trial Disease/Condition Indication | C112038 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | INTMODEL | Intervention Model | C98746 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | INTTYPE | Intervention Type | C98747 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | KEYWORD | Protocol Keyword | C126062 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | LENGTH | Trial Length | C49697 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | MNFCNTRY | Country of Manufacture | C124455 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | MSEUTIND | Multiple Site EU State Trial Indicator | C127794 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | NARMS | Planned Number of Arms | C98771 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | NCOHORT | Number of Groups/Cohorts | C126063 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | NUMSEUST | Number of Trial Sites EU State | C127795 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBJEXP | Trial Exploratory Objective | C163559 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBJPRIM | Trial Primary Objective | C85826 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBJSEC | Trial Secondary Objective | C85827 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBSMODEL | Observational Model | C126064 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBSTIMP | Observational Time Perspective | C126065 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBSTPOPD | Obs Study Population Description | C126066 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBSTSMM | Observational Study Sampling Method | C126067 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OBSTSMMD | Obs Study Sampling Method Description | C126068 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | ONGOSIND | Ongoing Study Indicator | C204699 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OUTMSADD | Additional Outcome Measure | C156601 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OUTMSEXP | Exploratory Outcome Measure | C98724 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OUTMSPRI | Primary Outcome Measure | C98772 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | OUTMSSEC | Secondary Outcome Measure | C98781 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PASSIND | Post Authorization Safety Study Ind | C139275 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PCLAS | Pharmacologic Class | C98768 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PDPSTIND | Pediatric Postmarket Study Indicator | C123631 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PDSTIND | Pediatric Study Indicator | C123632 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PIPIND | Pediatric Investigation Plan Indicator | C126069 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PLANSUB | Planned Number of Subjects | C49692 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PLNTRDUR | Planned Trial Duration | C127796 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PROTRSK | Protocol Risk Assessment | C139277 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PTRTDUR | Planned Treatment Duration | C139276 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | PUBMEDID | PubMed ID for Citation Used in Study | C127797 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | RANDOM | Trial is Randomized | C25196 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | RANDQT | Randomization Quotient | C98775 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | RDIND | Rare Disease Indicator | C126070 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | REGID | Registry Identifier | C98714 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | RESUBLTR | Resubmission Letter | C126071 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | RLPSCRIT | Relapse Criteria | C117961 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | ROUTE | Route of Administration | C38114 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | RTSPCDES | Retained Biospecimen Description | C126072 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | RXMLCIND | Request for XML Copy of Study Indicator | C127798 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SDMDUR | Stable Disease Minimum Duration | C98783 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SDTIGVER | SDTM IG Version | C156604 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SDTMDVER | SDTMIG Medical Device Version | C189317 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SDTMVER | SDTM Version | C156605 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SDXMLIND | Secure Delivery XML Required Indicator | C127799 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SENDTC | Study End Date | C90462 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SEVCRIT | Severity Criteria | C117962 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SEXPOP | Sex of Participants | C49696 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SPONSOR | Clinical Study Sponsor | C70793 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SPREFID | Sponsor's Study Reference ID | C135009 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SREVIND | SUSAR Reporting to EVCTM Indicator | C126073 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SRNCAIND | SUSAR Reporting to NCA Indicator | C126074 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SSEUTIND | Single Site EU State Trial Indicator | C127800 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SSTDTC | Study Start Date | C69208 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SSTDYDTL | Substudy Details | C126075 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | SSTDYIND | Substudy Planned Indicator | C126076 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | STOPRULE | Study Stop Rules | C49698 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | STRATFCT | Stratification Factor | C16153 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | STYPE | Study Type | C142175 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TBLIND | Trial Blinding Schema | C49658 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TCNTRL | Control Type | C49647 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TDIGRP | Diagnosis Group | C49650 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | THERAREA | Therapeutic Area | C101302 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TIGVER | Tobacco IG Version | C204700 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TINDTP | Trial Intent Type | C49652 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TITLE | Trial Title | C49802 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TPHASE | Trial Phase Classification | C48281 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TRGFUDUR | Target Follow-Up Duration | C126077 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TRT | Investigational Therapy or Treatment | C41161 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | TTYPE | Trial Type | C49660 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | URLSTDY | URL Related to Study | C127801 | C66738 | C67152 | TSPARM |
| 2024-03-29 | TSPARMCD | Paired | URLSTDYD | URL Related to Study Description | C127802 | C66738 | C67152 | TSPARM |